Free Trial
CVE:ZOM

Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM) Stock Price, News & Analysis

Zomedica Pharmaceuticals Corp. (ZOM.V) logo
C$0.28 -0.02 (-6.56%)
As of 02/5/2020

About Zomedica Pharmaceuticals Corp. (ZOM.V) Stock (CVE:ZOM)

Key Stats

Today's Range
C$0.29
C$0.29
50-Day Range
C$0.29
C$0.29
52-Week Range
C$0.29
C$1.50
Volume
4,800 shs
Average Volume
2,858 shs
Market Capitalization
C$36.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ZOM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zomedica Pharmaceuticals Corp. (ZOM.V) and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZOM Stock News Headlines

Zomedica Corp. trading halted, news pending
Zomedica Pharmaceuticals (ZOM) Receives a Buy from Noble Financial
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.tc pixel
Phio Pharmaceuticals Corp.
Zomedica Corp. (ZOM) Q2 2024 Earnings Call Transcript
Zomedica Corp Ordinary Shares ZOM
Zomedica Stock (AMEX:ZOM), Dividends
See More Headlines

ZOM Stock Analysis - Frequently Asked Questions

Zomedica Pharmaceuticals Corp. (ZOM.V)'s stock was trading at C$0.29 at the start of the year. Since then, ZOM stock has increased by 0.0% and is now trading at C$0.29.

Shares of ZOM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zomedica Pharmaceuticals Corp. (ZOM.V) investors own include Ocugen (OCGN), T2 Biosystems (TTOO), Meta Platforms (META), Bionano Genomics (BNGO), Onconova Therapeutics (ONTX), Biocept (BIOC) and Ford Motor (F).

Industry, Sector and Symbol

Stock Exchange
CVE
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Pharmaceutical Products
Current Symbol
CVE:ZOM
CIK
N/A
Fax
N/A
Employees
50
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
4.91
Current Ratio
15.31
Quick Ratio
15.25

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
C$0.05 per share
Price / Cash Flow
5.38
Book Value
C$0.05 per share
Price / Book
5.82

Miscellaneous

Outstanding Shares
128,872,000
Free Float
N/A
Market Cap
C$36.73 million
Optionable
Not Optionable
Beta
N/A
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (CVE:ZOM) was last updated on 9/3/2025 by MarketBeat.com Staff
From Our Partners